T. Rowe Price Investment Management Inc. increased its holdings in Humana Inc. (NYSE:HUM - Free Report) by 11.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,605,771 shares of the insurance provider's stock after buying an additional 160,952 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 1.33% of Humana worth $407,401,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Pinnacle Wealth Management Advisory Group LLC boosted its position in shares of Humana by 3.6% during the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock worth $272,000 after purchasing an additional 37 shares during the period. Atlas Brown Inc. lifted its holdings in shares of Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock valued at $1,611,000 after purchasing an additional 38 shares during the last quarter. Mather Group LLC. lifted its holdings in shares of Humana by 21.0% in the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock valued at $60,000 after purchasing an additional 41 shares during the last quarter. Capital Advisors Ltd. LLC raised its stake in Humana by 26.1% during the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock valued at $53,000 after acquiring an additional 43 shares during the last quarter. Finally, Retirement Planning Co of New England Inc. raised its stake in Humana by 4.7% during the 4th quarter. Retirement Planning Co of New England Inc. now owns 966 shares of the insurance provider's stock valued at $245,000 after acquiring an additional 43 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. Mizuho upped their price target on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Morgan Stanley reduced their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. Guggenheim assumed coverage on Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target for the company. Finally, Piper Sandler increased their target price on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research note on Wednesday, January 15th. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $284.90.
Read Our Latest Stock Report on HUM
Humana Price Performance
Shares of NYSE:HUM traded down $1.29 during trading on Tuesday, hitting $261.91. 592,933 shares of the company's stock were exchanged, compared to its average volume of 1,742,668. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The business's 50-day simple moving average is $266.31 and its 200 day simple moving average is $270.84. The company has a market cap of $31.61 billion, a price-to-earnings ratio of 26.32, a PEG ratio of 2.05 and a beta of 0.62.
Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities analysts predict that Humana Inc. will post 16.47 EPS for the current year.
Humana Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.35%. The ex-dividend date is Friday, June 27th. Humana's payout ratio is currently 35.58%.
Humana Company Profile
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
